American College Of Rheumatology
High-dose flu vaccines among the immunocompromised: ‘Not just for people older than 65’
All immunocompromised adults should receive the high-dose formulation of the influenza vaccine, according to a presenter at the Biologic Therapies Summit.
ACR endorses bipartisan bill to link Medicare physician fee schedule payments to inflation
The American College of Rheumatology has endorsed a newly introduced bill in Congress that would automatically adjust the Medicare physician fee schedule based on inflation.
ACR, AAHKS: Most patients indicated for hip, knee surgery should proceed without delay
Patients indicated for hip or knee arthroplasty who have moderate to severe osteoarthritis and have not responded to nonsurgical therapies should proceed to surgery without delay, according to new recommendations.
ACR applauds proposed prior authorization changes, urges shorter waits for urgent requests
The American College of Rheumatology has applauded CMS for recognizing, in its 2023 proposed rule on prior authorization, the “undue burden” the practice places on providers, according to a press release.
Medical groups push CMS to finalize proposed prior authorization reforms
The American Medical Association and 118 other medical societies, including the American College of Rheumatology, are urging CMS to finalize proposed rules aiming to reform prior authorization, according to a press release.
ACR urges CMS to revise policy excluding copay assistance from counting toward deductible
The American College of Rheumatology is urging CMS to reconsider its current policy of allowing insurers to exclude copay assistance programs from counting toward a patient’s deductible, according to a press release.
Just 63% of available pediatric rheumatology slots filled for Match Day 2023
Just 62.8% of available pediatric rheumatology program slots were filled for the 2023 appointment year as part of the National Residents Matching Program, according to the American College of Rheumatology.
Risankizumab improves symptoms, is well tolerated in psoriatic arthritis through 52 weeks
Risankizumab improves symptoms and is well tolerated through 52 weeks in patients with psoriatic arthritis who respond inadequately to biologic therapies or conventional synthetic disease-modifying antirheumatic drugs, according to data.
The anatomy of a meeting: Reflections on #ACR22
I just got back from Philadelphia and ACR Convergence 2022, and let me start by saying how glad I am that I attended. I met and canvassed the Healio Rheumatology Peer Board members, as well as a large number of friends and professional colleagues, on what they thought about the meeting in an effort to describe what worked for them, as well as what may have missed the mark.
New ACR/EULAR criteria for pediatric CNO include bone pain lasting at least 6 weeks
PHILADELPHIA — New classification criteria for pediatric chronic nonbacterial osteomyelitis include chronic bone pain or functional musculoskeletal limitation lasting 6 weeks or longer, according to a speaker at ACR Convergence 2022.